In patients with relapsed or refractory systemic lupus erythematosus, allogeneic CAR-NK cell therapy may offer a safe ...

In systemic lupus erythematosus, chronic spontaneous urticaria did not raise SLEDAI scores, but cylindruria, mucosal ulcers, ...

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that predisposes affected individuals to an elevated risk of cardiovascular disease (CVD). The intricate interplay of traditional ...

Background Cognitive impairment (CI) is one of the most common manifestations of neuropsychiatric systemic lupus ...

In the Phase 2b CARE study, the investigational drug, cenerimod, demonstrated safe and effective results for treatment of adults with moderate-to-severe systemic lupus erythematosus (SLE). The drug’s ...

In May, the German group that pioneered the treatment in rheumatic disease reported on a troubling syndrome they dubbed ...

Objective This study aimed to evaluate the prevalence and predictors of cardiovascular disease (CVD), chronic kidney disease ...

During the Phase IIb study (NCT05688696), 187 patients with SLE were randomised to receive 48 weeks of treatment with either 75mg or 50mg orelabrutinib or placebo. Within the 48-week treatment window, ...

Please provide your email address to receive an email when new articles are posted on . Early mycophenolate mofetil in newly diagnosed SLE led to fewer severe flares and lower incidence of lupus ...

Systemic lupus erythematosus (SLE) and primary biliary cirrhosis (PBC) are both chronic autoimmune diseases. PBC primarily affects the liver and is characterized by inflammation or swelling of the ...

Objectives The European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of systemic lupus erythematosus (SLE) and lupus nephritis provide important guidance for ...